HeartSciences Granted European Patent for Proprietary Electrode and Cable Connections for Use with its AI-Based MyoVista ECG

Southlake, TX — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW), a medical technology company focused on saving lives by making an ECG a far more valuable screening tool through the use of AI, today announced it has been granted a patent from the European Patent Office. The patent covers the design of the Company's electrode and cable connectors for use with an ECG, and in particular its MyoVista device.

"Millions of ECGs are performed every week. The electrodes used with the MyoVista are proprietary to HeartSciences. Adding Europe to our electrode patent coverage strengthens and diversifies our overall intellectual property portfolio as well as further protects future recurring revenues," said Andrew Simpson, CEO of HeartSciences.

"Unlike a conventional ECG, the MyoVista AI algorithm for cardiac dysfunction analyzes frequency signals from the heart. Our unique electrode design helps ensure an optimal, high quality, low impedance signal capture for each and every test. We have secured a number of U.S. and international patents and this most recent expansion of our IP portfolio is an example of how we continue to leverage our first mover advantage."